Loading...
•
Sep 30, 2024
REGENXBIO Q3 2024 Earnings Report
Reported financial results and operational highlights for Q3 2024.
Key Takeaways
REGENXBIO reported a net loss of $59.6 million for the third quarter of 2024, with revenues of $24.2 million. The company's cash, cash equivalents, and marketable securities totaled $278.6 million as of September 30, 2024, expected to fund operations into 2026. Key advancements include progress in the RGX-202 and ABBV-RGX-314 trials, and initiation of the BLA submission for RGX-121.
Advanced Phase I/II AFFINITY DUCHENNE trial of RGX-202 for Duchenne Muscular Dystrophy, with pivotal trial initiation and first functional data expected this month.
Initiated BLA submission for RGX-121, expected to be completed in Q1 2025.
Presented positive Phase II data supporting bilateral administration of subretinal ABBV-RGX-314, demonstrating a favorable safety and efficacy profile.
Accelerated End-of-Phase II meeting for ABBV-RGX-314 in diabetic retinopathy to Q4 2024, supporting global pivotal program initiation in H1 2025.
Revenue by Segment
Forward Guidance
REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $278.6 million as of September 30, 2024 to fund its operations into 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...